Compare the Difference Between Similar Terms

Difference Between MDS and Leukemia

Key Difference – MDS vs Leukemia
 

MDS and leukemia are due to the abnormalities in the bone marrows. Leukemia can be defined as the accumulation of abnormal malignant monoclonal white blood cells in the bone marrow. Myelodysplastic syndromes or MDS refer to a set of acquired bone marrow disorders that are due to the defects in the stem cells. Leukemia is a malignancy, but myelodysplasia is a precursor lesion that can undergo malignant transformation. This is the key difference between MDS and leukemia.

CONTENTS

1. Overview and Key Difference
2. What is MDS (Myelodysplastic Syndromes)
3. What is Leukemia
4. Similarities Between MDS and Leukemia
5. Side by Side Comparison – MDS vs Leukemia in Tabular Form
6. Summary

What is MDS?

Myelodysplastic syndromes (MDS) describe a set of acquired bone marrow disorders that are due to the defects in the stem cells. The characteristic feature of these disorders is the increasing bone marrow failure with both quantitative and qualitative abnormalities in the all the myeloid cell lineages (i.e. red blood cells, white blood cells, and platelets). Somatic point mutations in genes such as TP53 and E2H2 are believed to be the underlying cause of this condition.

Clinical Features

MDS is usually seen among elderly people. The most frequently observed manifestations are,

These features can be seen either individually or in conjunction with each other.

In spite of the presence of pancytopenia, the bone marrow shows increased cellularity. Dyserythropoiesis is a common complication. Granulocyte precursors and megakaryocytes have an abnormal morphology.

Figure 01: Myelodysplasia

WHO Classification of MDS

Disease

Marrow Blasts (%)

Clinical Presentation

Cytogenic Abnormalities (%)

Refractory anemia <5 Anemia 25
Refractory anemia with ring sideroblasts <5 Anemia, > 15 % ringed sideroblasts in the red cell precursors 5-20
MDS with isolated del <5 Anemia, normal platelets 100
Refractory cytopenia with multilineage dysplasia <5 Bicytopnenia or pancytopenia 50
Refractory anemia with excess blasts-1 5-9 Cytopenia with peripheral blood blasts (<5%) 30-50
Refractory anemia with excess blasts-1 10-19 Cytopenia with peripheral blood blasts 50-70
Myelodysplastic syndrome, unclassified <5 Neutropenia and thrombocytopenia 50

Investigations

Management

Patients with <5% of blasts in the bone marrow undergo a conservative management that includes,

If the percentage of blasts in the bone marrow is >5% the management is through the following procedures,

What is Leukemia?

Leukemia can be defined as the accumulation of abnormal malignant monoclonal white blood cells in the bone marrow. This results in bone marrow failure causing anemia, neutropenia, and thrombocytopenia. Normally, the proportion of blast cells in the adult bone marrow is less than 5%. But in the leukemic bone marrow, this proportion is over 20%.

Types of Leukemia

There are 4 basic subtypes of leukemia as,

These diseases are relatively uncommon and the annual incidence of them is 10/1000000. Usually, leukemia can occur at any age. But ALL is predominantly seen in the childhood whereas CLL frequently occurs in elderly. Etiological agents causing leukemia include radiation, viruses, cytotoxic agents, immunosuppression and genetic factors. Diagnosis of the disease can be done by the examination of a stained slide of peripheral blood and bone marrow. For sub-classification and prognostication, immunophenotyping, cytogenetics, and molecular genetics are essential.

Acute Leukemia

The incidence of acute leukemia increases with advancing age. The median age of presentation for acute myeloblastic leukemia is 65 years. Acute leukemia may arise de novo or due to prior cytotoxic chemotherapy or myelodysplasia. Acute lymphoblastic leukemia has a lower median age of presentation. It is the most common malignancy in the childhood.

Clinical Features of ALL

Clinical Features of AML

Investigations

For Confirmation of Diagnosis
For Planning Therapy

Management

Untreated acute leukemia is usually fatal. But with palliative treatment, the lifespan can be extended. Curative treatments can be sometimes successful. Failure can be due to relapse of the disease or due to complications of the therapy or because of the nonresponsive nature of the disease. In ALL, remission induction can be done with combination chemotherapy of Vincristine. For high-risk patients, allogeneic stem cell transplantation can be performed.

Chronic Myeloid Leukemia

CML is a member of the family of myeloproliferative neoplasms which exclusively occur in adults. It is defined by the presence of the Philadelphia chromosome and has a more slowly progressive course than acute leukemia.

Clinical Features

Investigations

Management

First line drug in the treatment of CML is Imatinib (Glivec), which is a tyrosine kinase inhibitor. Second line treatments include chemotherapy with hydroxyurea, alpha interferon, and allogeneic stem cell transplantation.

Chronic Lymphocytic Leukemia

CLL is the most common leukemia that mostly occurs in old age. It is caused due to clonal expansion of small B lymphocytes.

Clinical Features

Figure 02: Common Symptoms of Leukemia

Investigations

Management

Treatment is given to troublesome organomegaly, hemolytic episodes, and bone marrow suppression. Rituximab in combination with Fludarabine and cyclophosphamide show a dramatic response rate.

What are the Similarities Between MDS and Leukemia?

What is the Difference Between MDS and Leukemia?

MDS vs Leukemia

Myelodysplastic syndromes describe a set of acquired bone marrow disorders that are due to the defects in the stem cells. Leukemia can be defined as the accumulation of abnormal malignant monoclonal white blood cells in the bone marrow.
Type
This is a precursor lesion that has the potential of a malignant transformation. This is a malignancy.
Incidence
This is usually seen among elderly people. This can be seen in any age group but adults are more affected by this condition than the children.
Clinical Features
The common clinical features are,

·       Anemia

·       Bleeding due to pancytopenia

·       Neutropenia

·       Monocytosis

·       Thrombocytopenia

Frequently seen clinical features of leukemia are,

· Gum hypertrophy

· Violaceous skin deposits

· Fatigue and breathlessness

· Headache/confusion

· Infections

· Bone pain

· Bleeding and bruising

· Hepatosplenomegaly

· Testicular enlargement

· Lymphadenopathy

Management
Patients with <5% of blasts in the bone marrow undergo a conservative management that includes,

· Red cell and platelets transfusions

· Antibiotics for infection

If the percentage of blasts in the bone marrow is >5% the management is through the following procedures,

· Supportive care to minimize the risk of getting other complications

· Chemotherapy

· Administration of lenalidomide

Bone marrow transplantation

The management varies according to the type of leukemia that the patient has. Chemotherapy plays a major role in the treatment of leukemia.

Summary – MDS vs Leukemia

Myelodysplastic syndromes (MDS) describe a set of acquired bone marrow disorders that are due to the defects in the stem cells whereas Leukemia is the accumulation of abnormal malignant monoclonal white blood cells in the bone marrow. Myelodysplasia is a precursor lesion that can undergo malignant transformation but leukemia is a malignancy. This is the main difference between MDS and leukemia.

Download PDF Version of MDS vs Leukemia

You can download PDF version of this article and use it for offline purposes as per citation notes. Please download PDF version here Difference Between MDS and Leukemia

References:

1. Kumar, Parveen J., and Michael L. Clark. Kumar & Clark clinical medicine. Edinburgh: W.B. Saunders, 2009.

Image Courtesy:

1. “Granulocytic Dysplasia” By Emily Patonay – Own work (CC BY-SA 4.0) via Commons Wikimedia
2. “Symptoms of leukemia” By Mikael Häggström – (Public Domain) via Commons Wikimedia